Q-omics provides the consensus-scored SH2D3C profile across patient tissues and cancer cell-line models. SH2D3C expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SH2D3C is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, SH2D3C RNA expression shows 21,976 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where SH2D3C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SH2D3C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SH2D3C survival associations across molecular data types. SH2D3C RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SH2D3C RNA expression–survival associations across cancer types. High SH2D3C expression shows unfavorable associations in KIRP, UVM and SCLC, but favorable associations in HNSC, KIRC and PAAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SH2D3C RNA expression.
This table summarizes SH2D3C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SH2D3C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SH2D3C shows lower tumor expression in LUAD, KICH, KIRP and LUSC and higher tumor expression in KIRC and HNSC. The LUAD box plot shows higher SH2D3C RNA expression in normal versus tumor tissue (log2 FC = −2.393, t-test p < 0.001).
This table shows molecular features associated with SH2D3C in patient tissues and cancer cell lines. In patient samples, SH2D3C shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SH2D3C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
